



Respiratory Call: (877) 883-1392 Fax: (256) 429-2221

| Patient Information: | Name: | | | D | OB: | Gender: O | M OF Las | t 4 of SSN: | |
|-------------------------------|-------|-------|-------------|--------|----------|--------------|----------|-----------------------|--|
| Address: | | City: | | State: | Zip: | Phone: | | Alt. Phone: | |
| Email: | Ht: | | Care Giver: | | | Allergies: O | No Known | ○ See Attached Charts | |
| Prescriber Information | Name: | | | | Address: | | | City: | |
| State: Zip: | NPI: | | Pł | none: | | _ Fax: | Office | Contact: | |

Statement of Medical Necessity (Please Attach All Medical Documentation)

Date of Diagnosis: _____ ICD-10:

Other:

Date:

| Diagnosis of Mod-Sev Asthma in patients > 12 Years Old: | Prior Failed Treatments | Drug Name & Length of Treatment | | |
|---|---------------------------------------|------------------------------------|--|--|
| Diagnosed by: O Endoscopy O CT Scan | O Biologics | | | |
| Assessment: O Moderate O Mod to Severe O Severe | O ICS | | | |
| Number of severe exacerbations in the last 12 months that | O ICS + LABA | | | |
| required systemic corticosteroids, ER visits, or hospitalization: | O Intranasal | | | |
| Blood Eosinophil Level:Test Date: | Corticosteroids | | | |
| IgE Level (if atopic comorbidities): Test Date: | | | | |
| Pulmonary Function Test Results: | | | | |
| Pre-Bronchodilator FEV1: Test Date: | O Oral | | | |
| FeNO Levels (if applicable) Test Date: | Corticosteroids | | | |
| | Other Controllers | | | |
| | O Sinus Surgery | | | |

| Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) in patients >18 years old: | | | | | |
|--|------------------------------------|-------------------|-----------|--|--|
| Diagnosed by: | O Rhinoscopy | O Nasal Endoscopy | ○ CT Scan | | |
| Documentation of | Documentation of Ongoing Symptoms? | | | | |
| O Nasal Obstruction or Discharge O Facial Pain or Pressure | | | | | |
| O Reduction in c | or Loss of Smell | O N/A | | | |
| Results and date of last CT scan or endoscopy including polyp | | | | | |
| location/catheriza | ation, if applicable: | Test Date: | | | |

History of nasal surgeries and procedures? OYes ONo

O Endoscopic Polyp Removal (Polypectomy)

O Functional Endoscopic Sinus Surgery (FESS)

O Other:

If no, please state reason(s) patient may not be a candidate for surgery:

| Prior Failed Treatments | Drug Name & Length of Treatment |
|------------------------------|------------------------------------|
| O Oral Corticosteroids | |
| O Intranasal Corticosteroids | |
| ○ Surgery | |
| ○ Other | |

Injection Training:

- O Pharmacist to Provide Training
- O Patient Trained in MD Office
- Manufacturer Nurse Support

Product Delivery:

- Patient's Home
- \bigcirc Physician's Office
- O Pharmacy to Coordinate

Prescription Information:

| Medication | Dosage & Strength | Directions | Qty | Refills |
|------------|---|--|-----|---------|
| ODupixent | 200mg/1.14ml Prefilled Syringe 300mg/2ml Prefilled Syringe 300mg/2ml Prefilled Pen | For adults and adolescents 12 years of age and older: O Induction Dose: Inject 400mg SC on day one O Maintenance: Inject 200mg SC every other week | | 0 |
| | 200mg/1.14 mL Prefilled Pen For patients who require concomitant oral corticosteroids or with comborbid moderate to | O Induction Dose: Inject 600mg SC on day one O Maintenance: Inject 300mg SC every other week | 2 | 0 |
| | severe atopic dermatitis for which Dupixent® is indicated, start with an initial dose of 600mg SC followed by 300mg SC given every other week | For adults with chronic rhinosinusitis with nasal polyposis: O Inject 300mg SC every other week | 2 | |
| ONucala | <pre>O100mg/mL Prefilled Autoinjector O100mg/mL Prefilled Syringe</pre> | For adults and adolescents 12 years of age and older: O Inject 100mg SC once every 4 weeks | 1 | |
| 0 | 0 | 0 | | |

| Prescriber Signature (I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs) | | | | | |
|---|---------------------|-------|--|--|--|
| Signature: | Signature | Date: | | | |
| Substitution Permitted | Dispense as Written | | | | |
| Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among | | | | | |
| other things. Participation in this program is not a guarantee of prior authorization or of payment. | | | | | |
| | | | | | |

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately. Revised 10/31/2023